Myocardial biomarkers for prediction of cardiovascular disease

Disease Markers

Volumn 26, Issue 5-6, 2009, Pages 235-246

  Sundström, Johan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; Epidemiology; Myocardium; Peptide; Population; Risk

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BATIMASTAT; BIOLOGICAL MARKER; CHROMOGRANIN A; CONNECTIVE TISSUE GROWTH FACTOR; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; GALECTIN 3; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 10; INTERLEUKIN 6; MATRIX METALLOPROTEINASE INHIBITOR; MOLECULAR MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGLOBIN; MYOSIN LIGHT CHAIN; OSTEOPROTEGERIN; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; DISEASE MARKER; HIGH RISK POPULATION; HUMAN; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 70349931140     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/436740     Document Type: Review

References (129)

1. European Society of Cardiology, European Heart Network, European Commission, World Health Organization. The European Heart Health Charter. 6-12-2007. Ref Type: Internet Communication.
2. W.B. Kannel, D.R. Gagnon and L.A. Cupples, Epidemiology of sudden coronary death: population at risk, Can J Cardiol 6(10) (Dec 1990), 439-444.
3. S.E. Sheifer, T.A. Manolio and B.J. Gersh, Unrecognized Myocardial Infarction, Ann Intern Med 135(9) (6 Nov 2001), 801-811.
4. C. Ebeling Barbier, T. Bjerner, L. Johansson, L. Lind and H. Ahlstrom, Myocardial Scars More Frequent Than Expected: Magnetic Resonance Imaging Detects Potential Risk Group, Journal of the American College of Cardiology 48(4) (15 Aug 2006), 765-771.
5. W.B. Kannel, T.R. Dawber, A. Kagan, N. Revotskie and J. Stokes, III., Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study, Ann Intern Med 55 (Jul 1961), 33-50.
6. A.D. Lopez, C.D. Mathers, M. Ezzati, D.T. Jamison and C.J. Murray, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data, The Lancet 367(9524), 1747-1757.
7. P.N. Hopkins and R.R. Williams, A survey of 246 suggested coronary risk factors, Atherosclerosis 40(1) (1981), 1-52.
8. R.S. Vasan, L.M. Sullivan, P.W. Wilson, C.T. Sempos, J. Sundstrom, W.B. Kannel et al., Relative importance of borderline and elevated levels of coronary heart disease risk factors, Ann Intern Med 142(6) (15 Mar 2005), 393-402.
9. T.A. Gaziano, C.R. Young, G. Fitzmaurice, S. Atwood and J.M. Gaziano, Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort, Lancet 371(9616) (15 Mar 2008), 923-931.
10. D.A. Morrow and J.A. de Lemos. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers, Circulation 115(8) (27 Feb 2007), 949-952.
11. M.J. Pencina, R.B. D'Agostino, Sr., R.B. D'Agostino, Jr. and R.S. Vasan, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med 27(2) (30 Jan 2008), 157-172.
12. K.T. Weber and C.G. Brilla, Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system, Circulation 83(6) (1 Jun 1991), 1849.
13. K. Thygesen, J.S. Alpert and H.D. White, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, TASKFORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), Biomarker Group: Allan S. Jaffe CU, et al. Universal Definition of Myocardial Infarction, Circulation 116(22) (27 Nov 2007), 2634-2653.
14. H. Steen, S. Futterer, C. Merten, C. Junger, H.A. Katus and E. Giannitsis, Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction, J Cardiovasc Magn Reson 9(5) (2007), 749-758.
15. D.A. Morrow, C.P. Cannon, N. Rifai, M.J. Frey, R. Vicari, N. Lakkis et al., Ability of Minor Elevations of Troponins I and T to Predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial Infarction: Results From a Randomized Trial, JAMA: the Journal of the American Medical Association 286(19) (21 Nov 2001), 2405-2412.
16. J.J. You, P.C. Austin, D.A. Alter, D.T. Ko and J.V. Tu, Relation between cardiac troponin I and mortality in acute decompensated heart failure, American Heart Journal 153(4) (Apr 2007), 462-470. (Pubitemid 46440690)
17. C.H. Del Carlo, A.C. Pereira-Barretto, C. Cassaro-Strunz, M.D.R. Latorre and J.A.F. Ramires, Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure, Journal of Cardiac Failure 10(1) (Feb 2004), 43-48.
18. W.F. Peacock, I.V, T. De Marco, G.C. Fonarow, D. Diercks, J. Wynne, F.S. Apple et al., Cardiac Troponin and Outcome in Acute Heart Failure, N Engl J Med 358(20) (15 May 2008), 2117-2126. (Pubitemid 351679598)
19. R. Latini, S. Masson, I.S. Anand, E. Missov, M. Carlson, T. Vago et al., Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure, Circulation 116(11) (11 Sep 2007), 1242-1249.
20. W.L. Miller, K.A. Hartman, M.F. Burritt, D.E. Grill, R.J. Rodeheffer, J.C. Burnett, Jr. et al., Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time, Circulation 116(3) (17 Jul 2007), 249-257.
21. Y. Sato, T. Yamada, R. Taniguchi, K. Nagai, T. Makiyama, H. Okada et al., Persistently Increased Serum Concentrations of Cardiac Troponin T in Patients With Idiopathic Dilated Cardiomyopathy Are Predictive of Adverse Outcomes, Circulation 103(3) (23 Jan 2001), 369-374.
22. T.B. Horwich, J. Patel, W.R. MacLellan and G.C. Fonarow, Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure, Circulation 108(7) (19 Aug 2003), 833-838.
23. C. deFilippi, S. Wasserman, S. Rosanio, E. Tiblier, H. Sperger, M. Tocchi et al., Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis, JAMA: the Journal of the American Medical Association 290(3) (16 Jul 2003), 353-359.
24. B. Zethelius, N. Johnston and P. Venge, Troponin I as a Predictor of Coronary Heart Disease and Mortality in 70-Year-Old Men: A Community-Based Cohort Study, Circulation 113(8) (28 Feb 2006), 1071-1078.
25. B. Zethelius, L. Berglund, J. Sundstrom, E. Ingelsson, S. Basu, A. Larsson et al., Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes, N Engl J Med 358(20) (15 May 2008), 2107-2116.
26. R.E. Fromm, Jr., Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation, Crit Care Med 35(2) (Feb 2007), 584-588.
27. N. Mahajan, Y. Mehta, M. Rose, J. Shani and E. Lichstein, Elevated troponin level is not synonymous with myocardial infarction, International Journal of Cardiology 111(3) (28 Aug 2006), 442-449. (Pubitemid 44205299)
28. T.K. Bakshi, M.K.F. Choo, C.C. Edwards, A.G. Scott, H.H. Hart and G.P. Armstrong, Causes of elevated troponin I with a normal coronary angiogram, Internal Medicine Journal 32(11) (30 Nov 2002), 520-525.
29. B.J. Freda, W.H.W. Tang, F. Van Lente, W.F. Peacock and G.S. Francis, Cardiac troponins in renal insufficiency: Review and clinical implications, Journal of the American College of Cardiology 40(12) (18 Dec 2002), 2065-2071. (Pubitemid 36005889)
30. T.J. Wang, Significance of Circulating Troponins in Heart Failure: If These Walls Could Talk, Circulation 116(11) (11 Sep 2007), 1217-1220.
31. J.P. Bertinchant, E. Robert, A. Polge, C. Marty-Double, P. Fabbro-Peray, S. Poirey et al., Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats, Clinica Chimica Acta 298(1-2) (Aug 2000), 13-28.
32. J.L. McDonough, D.K. Arrell and J.E. Van Eyk, Troponin I Degradation and Covalent Complex Formation Accompanies Myocardial Ischemia/Reperfusion Injury, Circ Res 84(1) (22 Jan 1999), 9-20.
33. A. Maekawa, J.K. Lee, T. Nagaya, K. Kamiya, K. Yasui, M. Horiba et al., Overexpression of calpastatin by gene transfer prevents troponin I degradation and ameliorates contractile dysfunction in rat hearts subjected to ischemia/reperfusion, Journal of Molecular and Cellular Cardiology 35(10) (Oct 2003), 1277-1284.
34. W. Wang, C.J. Schulze, W.L. Suarez-Pinzon, J.R.B. Dyck, G. Sawicki and R. Schulz, Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury, Circulation 106(12) (17 Sep 2002), 1543-1549.
35. H. Yasue, M. Yoshimura, H. Sumida, K. Kikuta, K. Kugiyama, M. Jougasaki et al., Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure, Circulation 90(1) (Jul 1994), 195-203.
36. D. Konig, O. Neubauer, L. Nics, N. Kern, A. Berg, E. Bisse et al., Biomarkers of exercise-induced myocardial stress in relation to inflammatory and oxidative stress, Exerc Immunol Rev 13 (2007), 15-36.
37. J. Januzzi, A. Morss, R. Tung, R. Pino, M. Fifer, B.T. Thompson et al., Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study, Critical Care 10(1) (2006), R37.
38. O. Bazzino, J.J. Fuselli, F. Botto, D. Perez de Arenaza, C. Bahit, J. Dadone et al., Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes, European Heart Journal 25(10) (2 May 2004), 859-866.
39. S.K. James, B. Lindahl, A. Siegbahn, M. Stridsberg, P. Venge, P. Armstrong et al., N-Terminal Pro-Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV Substudy, Circulation 108(3) (22 Jul 2003), 275-281.
40. J.A. de Lemos, D.A. Morrow, J.H. Bentley, T. Omland, M.S. Sabatine, C.H. McCabe et al., The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes, N Engl J Med 345(14) (4 Oct 2001), 1014-1021. (Pubitemid 34940793)
41. C. Kragelund, B. Gronning, L. Kober, P. Hildebrandt and R. Steffensen, N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease, N Engl J Med 352(7) (17 Feb 2005), 666-675. (Pubitemid 40239214)
42. K. Bibbins-Domingo, R. Gupta, B. Na, A.H.B. Wu, N.B. Schiller and M.A. Whooley, N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease, JAMA: the Journal of the American Medical Association 297(2) (10 Jan 2007), 169-176.
43. C. Kistorp, I. Raymond, F. Pedersen, F. Gustafsson, J. Faber and P. Hildebrandt, N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults, JAMA: the Journal of the American Medical Association 293(13) (6 Apr 2005), 1609-1616.
44. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, T. Omland et al., Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death, N Engl J Med 350(7) (12 Feb 2004), 655-663. (Pubitemid 38364624)
45. G.C. Fonarow, W.F. Peacock, C.O. Phillips, M.M. Givertz and M. Lopatin, Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure, Journal of the American College of Cardiology 49(19) (15 May 2007), 1943-1950. (Pubitemid 46694287)
46. R. Valle, N. Aspromonte, M. Feola, M. Milli, C. Canali, P. Giovinazzo et al., B-Type Natriuretic Peptide Can Predict the Medium-Term Risk in Patients With Acute Heart Failure and Preserved Systolic Function, Journal of Cardiac Failure 11(7) (Sep 2005), 498-503.
47. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc et al., Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure, N Engl J Med 347(3) (18 Jul 2002), 161-167. (Pubitemid 34764819)
48. L.B. Daniels and A.S. Maisel, Natriuretic Peptides, Journal of the American College of Cardiology 50(25), 2357-2368.
49. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, P.W.F. Wilson et al., Impact of Obesity on Plasma Natriuretic Peptide Levels, Circulation 109(5) (10 Feb 2004), 594-600. (Pubitemid 38198866)
50. M. Shimpo, D.A. Morrow, E.O. Weinberg, M.S. Sabatine, S.A. Murphy, E.M. Antman et al., Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction, Circulation 109(18) (11 May 2004), 2186-2190.
51. J.L. Januzzi, Jr., W.F. Peacock, A.S. Maisel, C.U. Chae, R.L. Jesse, A.L. Baggish et al., Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea: Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study, Journal of the American College of Cardiology 50(7) (14 Aug 2007), 607-613.
52. S.U. Rehman, T. Mueller and J.L. Januzzi, Jr., Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure, Journal of the American College of Cardiology 52(18) (28 Oct 2008), 1458-1465.
53. E.O. Weinberg, M. Shimpo, S. Hurwitz, S.I. Tominaga, J.L. Rouleau and R.T. Lee, Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker, Circulation 107(5) (11 Feb 2003), 721-726.
54. T. Kempf, M. Eden, J. Strelau, M. Naguib, C. Willenbockel, J. Tongers et al., The Transforming Growth Factor-{beta} Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury, Circ Res 98(3) (17 Feb 2006), 351-360.
55. D.A. Brown, S.N. Breit, J. Buring, W.D. Fairlie, A.R. Bauskin, T. Liu et al., Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study, The Lancet 359(9324) (22 Jun 2002), 2159-2163.
56. T. Kempf, E. Bjorklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter et al., Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction, European Heart Journal 28(23) (1 Dec 2007), 2858-2865. (Pubitemid 350233034)
57. K.C. Wollert, T. Kempf, T. Peter, S. Olofsson, S. James, N. Johnston et al., Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non-ST-Elevation Acute Coronary Syndrome, Circulation 115(8) (27 Feb 2007), 962-971. (Pubitemid 46328289)
58. T. Kempf, S. von Haehling, T. Peter, T. Allhoff, M. Cicoira, W. Doehner et al., Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure, Journal of the American College of Cardiology 50(11) (11 Sep 2007), 1054-1060. (Pubitemid 47348231)
59. L. Taupenot, K.L. Harper and D.T. O'Connor, The Chromogranin- Secretogranin Family, N Engl J Med 348(12) (20 Mar 2003), 1134-1149.
60. M. Pieroni, A. Corti, B. Tota, F. Curnis, T. Angelone, B. Colombo et al., Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function, European Heart Journal 28(9) (1 May 2007), 1117-1127.
61. M.E. Estensen, A. Hognestad, U. Syversen, I. Squire, L. Ng, J. Kjekshus et al., Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction, Am Heart J 152(5) (Nov 2006), 927-1926
62. T. Omland, K. Dickstein and U. Syversen, Association between plasma chromogranin a concentration and long-term mortality after myocardial infarction, The American Journal of Medicine 114(1) (Jan 2003), 25-30. (Pubitemid 36126512)
63. T. Ueland, A. Yndestad, E. Oie, G. Florholmen, B. Halvorsen, S.S. Froland et al., Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure, Circulation 111(19) (17 May 2005), 2461-2468.
64. T. Omland, T. Ueland, A.M. Jansson, A. Persson, T. Karlsson, C. Smith et al., Circulating Osteoprotegerin Levels and Long- Term Prognosis in Patients With Acute Coronary Syndromes, Journal of the American College of Cardiology 51(6) (12 Feb 2008), 627-633.
65. T. Ueland, R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland et al., Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction, J Am Coll Cardiol 44(10) (16 Nov 2004), 1970-1976. (Pubitemid 39473280)
66. S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr et al., Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease, Circulation 109(18) (11 May 2004), 2175-2180. (Pubitemid 38625393)
67. W.S. Browner, L.Y. Lui and S.R. Cummings, Associations of Serum Osteoprotegerin Levels with Diabetes, Stroke, Bone Density, Fractures, and Mortality in Elderly Women, J Clin Endocrinol Metab 86(2) (1 Feb 2001), 631-637.
68. T. Sugiura, H. Takase, T. Toriyama, T. Goto, R. Ueda and Y. Dohi, Circulating Levels of Myocardial Proteins Predict Future Deterioration of Congestive Heart Failure, Journal of Cardiac Failure 11(7) (Sep 2005), 504-509.
69. M. O'Donoghue, J.A. de Lemos, D.A. Morrow, S.A. Murphy, J.L. Buros, C.P. Cannon et al., Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes, Circulation 114(6) (8 Aug 2006), 550-557.
70. J. Ishii, Y. Ozaki, J. Lu, F. Kitagawa, T. Kuno, T. Nakano et al., Prognostic Value of Serum Concentration of Heart-Type Fatty Acid-Binding Protein Relative to Cardiac Troponin T on Admission in the Early Hours of Acute Coronary Syndrome, Clin Chem 51(8) (1 Aug 2005), 1397-1404.
71. J. Ravkilde, H. Nissen, M. Horder and K. Thygesen, Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction: Analysis of 28 months of follow-up in 196 patients, Journal of the American College of Cardiology 25(3) (1 Mar 1995), 574-581.
72. G.S. Hillis, P. Taggart, D. Wardlaw, L. Hillis, N. Zhao, W.C. Dalsey et al., The relative utility of cardiac troponin I, creatine kinase-MBmass, and myosin light chain-1 in the long-term risk stratification of patients with chest pain, Clin Cardiol 26(3) (Mar 2003), 147-152.
73. J.M. Galla, K.W. Mahaffey, S.K. Sapp, J.H. Alexander, M.T. Roe, E.M. Ohman et al., Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials, American Heart Journal 151(1) (Jan 2006), 16-24.
74. J.H. Alexander, R.A. Sparapani, K.W. Mahaffey, J.W. Deckers, L.K. Newby, E.M. Ohman et al., Association Between Minor Elevations of Creatine Kinase-MB Level and Mortality in Patients With Acute Coronary Syndromes Without ST-Segment Elevation. JAMA: the Journal of the American Medical Association 283(3) (19 Jan 2000), 347-353.
75. A. Isakov, I. Shapira, M. Burke and C. Almog, Serum myoglobin levels in patients with ischemic myocardial insult, Arch Intern Med 148(8) (Aug 1988), 1762-1765.
76. M.C. Kontos, R. Garg, F.P. Anderson, C.S. Roberts, J.P. Ornato, J.L. Tatum et al., Ability of myoglobin to predict mortality in patients admitted for exclusion of myocardial infarction, The American Journal of Emergency Medicine 25(8) (Oct 2007), 873-879.
77. E. Ingelsson, J. Arnlov, J. Sundstrom and L. Lind, Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure, J Am Coll Cardiol 45(11) (7 Jun 2005), 1802-1806.
78. K. Yamauchi-Takihara, Y. Ihara, A. Ogata, K. Yoshizaki, J. Azuma and T. Kishimoto, Hypoxic Stress Induces Cardiac Myocyteû Derived Interleukin-6, Circulation 91(5) (1 Mar 1995), 1520-1524.
79. M. Cesari, B.W.J.H. Penninx, A.B. Newman, S.B. Kritchevsky, B.J. Nicklas, K. Sutton-Tyrrell et al., Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study, Circulation 108(19) (11 Nov 2003), 2317-2322. (Pubitemid 37413536)
80. R.S. Vasan, L.M. Sullivan, R. Roubenoff, C.A. Dinarello, T. Harris, E.J. Benjamin et al., Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study, Circulation 107(11) (25 Mar 2003), 1486-1491. (Pubitemid 36378485)
81. T. Tsutamoto, T. Hisanaga, A. Wada, K. Maeda, M. Ohnishi, D. Fukai et al., Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure, Journal of the American College of Cardiology 31(2) (1 Feb 1998), 391-398.
82. L. Gullestad, H. Aass, J.G. Fjeld, L. Wikeby, A.K. Andreassen, H. Ihlen et al., Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure, 0Circulation 103(2) (16 Jan 2001), 220-225. (Pubitemid 32095406)
83. F. Kuwahara, H. Kai, K. Tokuda, M. Takeya, A. Takeshita, K. Egashira et al., Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation? Hypertension 43(4) (1 Apr 2004), 739-745. (Pubitemid 38405580)
84. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.E. van Berlo, J.P.M. Cleutjens, B. Schroen et al., Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction, Circulation 110(19) (9 Nov 2004), 3121-3128.
85. R.R. van Kimmenade, J.L. Januzzi, Jr., P.T. Ellinor, U.C. Sharma, J.A. Bakker, A.F. Low et al., Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure, J Am Coll Cardiol 48(6) (19 Sep 2006), 1217-1224. (Pubitemid 44345127)
86. N. Koitabashi, M. Arai, K. Niwano, A. Watanabe, M. Endoh, M. Suguta et al., Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure, European Journal of Heart Failure 10(4) (Apr 2008), 373-379.
87. M.M. Chen, A. Lam, J.A. Abraham, G.F. Schreiner and A.H. Joly, CTGF Expression is Induced by TGF- [beta] in Cardiac Fibroblasts and Cardiac Myocytes: a Potential Role in Heart Fibrosis, Journal of Molecular and Cellular Cardiology 32(10) (Oct 2000), 1805-1819.
88. B. Devaux, D. Scholz, A. Hirche, W.P. Klovekorn and J. Schaper, Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure, European Heart Journal 18(3) (1 Mar 1997), 470-479.
89. D.L. Mann, Targeted Anticytokine Therapy and the Failing Heart, The American Journal of Cardiology 95(11, Supplement 1) (6 Jun 2005), 9-16.
90. J. Sundstrom and R.S. Vasan, Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events, Curr Opin Lipidol 17(1) (Feb 2006), 45-53.
91. G. Klappacher, P. Franzen, D. Haab, M. Mehrabi, M. Binder, K. Plesch et al., Measuring Extracellular Matrix Turnover in the Serum of Patients With Idiopathic or Ischemic Dilated Cardiomyopathy and Impact on Diagnosis and Prognosis, The American Journal of Cardiology 75(14) (1 May 1995), 913-918.
92. R. Querejeta, N. Varo, B. Lopez, M. Larman, E. Artinano, J.C. Etayo et al., Serum Carboxy-Terminal Propeptide of Procollagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease, Circulation 101(14) (11 Apr 2000), 1729-1735.
93. R. Querejeta, B. Lopez, A. Gonzalez, E. Sanchez, M. Larman, J.L. Martinez Ubago et al., Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis, Circulation 110(10) (7 Sep 2004), 1263-1268.
94. J. Sundstrom, J.C. Evans, E.J. Benjamin, D. Levy, M.G. Larson, D.B. Sawyer et al., Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study, Eur Heart J 25(17) (Sep 2004), 1509-1516. (Pubitemid 39165629)
95. J. Sundstrom, J.C. Evans, E.J. Benjamin, D. Levy, M.G. Larson, D.B. Sawyer et al., Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study, Circulation 109(23) (15 Jun 2004), 2850-2856. (Pubitemid 38786446)
96. J. Hansson, L. Lind, J. Hulthe and J. Sundström, Relations of Serum MMP-9 and TIMP-1 Levels to Left Ventricular Measures and Cardiovascular Risk Factors: A Population- Based Study, Eur J Cardiovasc Prev Rehabil (2008), in press.
97. E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks and J.C. Kaski, Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris, Circulation 110(13) (28 Sep 2004), 1747-1753. (Pubitemid 39299216)
98. S. Blankenberg, H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner et al., Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease, Circulation 107(12) (1 Apr 2003), 1579.
99. E. Cavusoglu, C. Ruwende, V. Chopra, S. Yanamadala, C. Eng, L.T. Clark et al., Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction, American Heart Journal 151(5) (May 2006), 1101.
100. E. Lubos, R. Schnabel, H.J. Rupprecht, C. Bickel, C.M. Messow, S. Prigge et al., Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study, European Heart Journal 27(2) (2 Jan 2006), 150-156.
101. N.B. Host, L.T. Jensen, P.M. Bendixen, S.E. Jensen, O.G. Koldkjaer and E.E. Simonsen, The Aminoterminal Propeptide of Type III Procollagen Provides New Information on Prognosis After Acute Myocardial Infarction, The American Journal of Cardiology 76(12) (1 Nov 1995), 869-873.
102. S.H. Poulsen, N.B. Host, S.E. Jensen and K. Egstrup, Relationship Between Serum Amino-Terminal Propeptide of Type III Procollagen and Changes of Left Ventricular Function After Acute Myocardial Infarction, Circulation 101(13) (4 Apr 2000), 1527-1532.
103. M.G. Modena, R. Molinari, R. Rossi, N. Muia, Jr., A. Castelli, G. Mattioli et al., Modification in serum concentrations of aminoterminal propeptide of type III procollagen in patients with previous transmural myocardial infarction, Am Heart J 135(2 Pt 1) (Feb 1998), 287-292.
104. S.H. Poulsen, N.B. Host and K. Egstrup, Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction, Cardiology 96(1) (2001), 45-50.
105. T. Takino, M. Nakamura and K. Hiramori, Circulating levels of carboxyterminal propeptide of type I procollagen and left ventricular remodeling after myocardial infarction, Cardiology 91(2) (1999), 81-86. (Pubitemid 29371545)
106. F. Zannad, F. Alla, B. Dousset, A. Perez and B. Pitt, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators, Circulation 102(22) (28 Nov 2000), 2700-2706.
107. Y. Sato, K. Kataoka, A. Matsumori, S. Sasayama, T. Yamada, H. Ito et al., Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy, Heart 78(5) (1 Nov 1997), 505.
108. P.M. Timms, N. Mannan, G.A. Hitman, K. Noonan, P.G. Mills, D. Syndercombe-Court et al., Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95(12) (Dec 2002), 787-796.
109. P. Carmeliet, L. Moons, R. Lijnen, M. Baes, V. Lemaitre, P. Tipping et al., Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation, Nat Genet 17(4) (Dec 1997), 439-444.
110. E. Lee, D.E. Vaughan, S.H. Parikh, A.J. Grodzinsky, P. Libby, M.W. Lark et al., Regulation of Matrix Metalloproteinases and Plasminogen Activator Inhibitor-1 Synthesis by Plasminogen in Cultured Human Vascular Smooth Muscle Cells, Circ Res 78(1)(1 Jan 1996), 44-49. (Pubitemid 26004119)
111. N.B. Host, S.S. Hansen, L.T. Jensen, D. Husum and J.D. Nielsen, Thrombolytic therapy of acute myocardial infarction alters collagen metabolism, Cardiology 85(5) (1994), 323-333. (Pubitemid 24337743)
112. K.J. Peuhkurinen, L. Risteli, J.T. Melkko, M. Linnaluoto, A. Jounela and J. Risteli, Thrombolytic therapy with streptokinase stimulates collagen breakdown, Circulation 83(6) (Jun 1991), 1969-1975.
113. K.K. Koh, J.W. Son, J.Y. Ahn, D.K. Jin, H.S. Kim, Y.M. Choi et al., Comparative Effects of Diet and Statin on NO Bioactivity and Matrix Metalloproteinases in Hypercholesterolemic Patients With Coronary Artery Disease, Arterioscler Thromb Vasc Biol 22(9) (1 Sep 2002), 19e-23e.
114. K.K. Koh, J.W. Son, J.Y. Ahn, Y.M. Choi, D.K. Jin, G.S. Park et al., Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet, Coron Artery Dis 12(4) (Jun 2001), 305-311.
115. A. Kalela, R. Laaksonen, T. Lehtimaki, T.A. Koivu, M. Hoyhtya, T. Janatuinen et al., Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases, The American Journal of Cardiology 88(2) (15 Jul 2001), 173-175. (Pubitemid 32607707)
116. K.J. Molloy, M.M. Thompson, E.C. Schwalbe, P.R.F. Bell, A.R. Naylor and I.M. Loftus, Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively, The American Journal of Cardiology 94(1) (1 Jul 2004), 144-146.
117. S.M. Haffner, A.S. Greenberg, W.M. Weston, H. Chen, K. Williams and M.I. Freed, Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus, Circulation 106(6) (6 Aug 2002), 679-684. (Pubitemid 34851926)
118. N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt et al., Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease, Arterioscler Thromb Vasc Biol 23(2) (1 Feb 2003), 283.
119. J. Diez, C. Laviades, G. Mayor, M.J. Gil and I. Monreal, Increased Serum Concentrations of Procollagen Peptides in Essential Hypertension: Relation to Cardiac Alterations, Circulation 91(5) (1 Mar 1995), 1450-1456.
120. I. Ebihara, T. Nakamura, N. Shimada and H. Koide, Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus, Am J Kidney Dis 32(4) (Oct 1998), 544-550. (Pubitemid 28477698)
121. C. Laviades, N. Varo, J. Fernandez, G. Mayor, M.J. Gil, I. Monreal et al., Abnormalities of the Extracellular Degradation of Collagen Type I in Essential Hypertension, Circulation 98(6) (11 Aug 1998), 535-540.
122. M. Matoba, T. Asaji, S. Matsui and N. Takekoshi, Longterm effects of delapril hydrochloride on procollagen type III amino-terminal peptide, left ventricular mass and left ventricular function in hypertensive patients, Jpn Circ J 62(12) (Dec 1998), 900-902. (Pubitemid 28566730)
123. M. Sasaguri, K. Noda, E. Tashiro, J. Notomo, E. Tsuji, M. Koga et al., The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients, Hypertens Res 23(4) (Jul 2000), 317-322.
124. A. Sato, H. Takane and T. Saruta, High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients, Hypertens Res 24(2) (Mar 2001), 99-104.
125. J. Diez, R. Querejeta, B. Lopez, A. Gonzalez, M. Larman and J.L. Martinez Ubago, Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients, Circulation 105(21) (28 May 2002), 2512-2517.
126. B. Lopez, R. Querejeta, N. Varo, A. Gonzalez, M. Larman, J.L. Martinez Ubago et al., Usefulness of Serum Carboxy- Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients, Circulation 104(3) (17 Jul 2001), 286-291.
127. L. Gullestad, T. Ueland, J.G. Fjeld, E. Holt, T. Gundersen, K. Breivik et al., Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure:
128. C.M. Araujo, G.A. Rando, M.F. Mauro, S.A. Cristovao, I.S. Sanchez, A.A. Salman et al., Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study, Arq Bras Cardiol 84(3) (Mar 2005), 256-260. (Pubitemid 40562385)
129. T.J. Wang, P. Gona, M.G. Larson, G.H. Tofler, D. Levy, C. Newton-Cheh et al., Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death, N Engl J Med 355(25) (21 Dec 2006), 2631-2639. (Pubitemid 44969122)